Trial Profile
A Multicenter Randomized Phase 2 Trial to Evaluate the Triplet Combination of Raltitrexed, Oxaliplatin and Bevacizumab Versus FOLFOX6 Plus Bevacizumab in Second-line Treatment of Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Oxaliplatin (Primary) ; Raltitrexed (Primary) ; Fluorouracil; Levofolinic acid
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms BEVATOMOX
- 24 Dec 2019 Status changed from active, no longer recruiting to discontinued.
- 12 Sep 2017 Results assessing the efficacy of raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer, were presented at the 42nd European Society for Medical Oncology Congress.
- 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.